ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
127.128,06
-0,37%
S&P 500
6.013,13
-1,71%
US Dollar vs BRL
5,7351
0,05%
Bitcoin
95.741,46
-0,55%
Brent Oil
73,955
-0,20%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Prana Biotechnology Ltd ADS (PRAN)

  7. Prana Biotechnology Ltd ADS (PRAN) Notícias

PRAN

Prana Biotechnology Ltd ADS (PRAN)

Prana Biotechnology Ltd ADS
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PRAN
DataHoraFonteTítuloCódigoCompanhia
31/01/201912:01Business WirePrana Receives First Orphan Drug Designation from the FDA for the Treatment of Multiple System AtrophyNASDAQ:PRANPrana Biotechnology Ltd ADS
02/01/201910:00PR Newswire (US)Life Biosciences LLC leads strategic investment of up to A$44.5 million (US$31.4 million) in PranaNASDAQ:PRANPrana Biotechnology Ltd ADS
05/10/201800:47Business WirePrana Biotechnology: Pre-Clinical Evidence Demonstrates PBT434 as a Potential Treatment for MSANASDAQ:PRANPrana Biotechnology Ltd ADS
04/09/201807:22Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:PRANPrana Biotechnology Ltd ADS
08/07/201821:15Business WirePBT434 Data to be Presented at the International Congress of Parkinson’s Disease and Movement DisordersNASDAQ:PRANPrana Biotechnology Ltd ADS
03/07/201822:38Business WireFirst Volunteers Dosed in Phase I Clinical Trial of PBT434, Prana’s Lead Therapy for Parkinsonian DiseasesNASDAQ:PRANPrana Biotechnology Ltd ADS
13/06/201821:55Business WirePrana to Commence Phase 1 Clinical Trial of PBT434 for Treatment of Parkinsonian DiseasesNASDAQ:PRANPrana Biotechnology Ltd ADS
18/07/201710:00Business WirePrana Commences Research Collaboration with Takeda for the Treatment of Parkinson's Disease Gastrointestinal NeuropathologyNASDAQ:PRANPrana Biotechnology Ltd ADS
05/07/201710:00Business WirePrana's PBT434 Lowers Alpha-Synuclein and Prevents NeurodegenerationNASDAQ:PRANPrana Biotechnology Ltd ADS
05/06/201709:30Business WirePrana Appoints David Stamler as Chief Medical Officer to Lead Clinical DevelopmentNASDAQ:PRANPrana Biotechnology Ltd ADS
18/10/201613:00Business WireNew Data from Reach2HD Trial Presented at American Neurological Association Annual MeetingNASDAQ:PRANPrana Biotechnology Ltd ADS
27/07/201613:22Business WirePrana Alzheimer's disease data features at world leading conferenceNASDAQ:PRANPrana Biotechnology Ltd ADS
11/04/201609:00Business WirePrana Regains Compliance with NASDAQ Continued Listing Requirements Continues to Work Towards FDA SubmissionNASDAQ:PRANPrana Biotechnology Ltd ADS
26/02/201610:00Business WirePrana Biotechnology Half Year Investor ReportNASDAQ:PRANPrana Biotechnology Ltd ADS
16/11/201512:00Business WirePrana Chief Scientific Advisor Receives Smithsonian American Ingenuity AwardNASDAQ:PRANPrana Biotechnology Ltd ADS
09/11/201511:00Business WirePrana Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price RequirementNASDAQ:PRANPrana Biotechnology Ltd ADS
27/08/201509:00Business WirePrana Reports FY15 Financial ResultsNASDAQ:PRANPrana Biotechnology Ltd ADS
24/07/201510:00PR Newswire (US)Technical Report on Drug Manufacturers - Other Stocks -- Synergy Pharma, Teva Pharma, Orexigen Therapeutics, Prana Biotechnol...NASDAQ:PRANPrana Biotechnology Ltd ADS
01/07/201500:58Business WirePrana Announces Safety Outcomes of Alzheimer’s IMAGINE Extension TrialNASDAQ:PRANPrana Biotechnology Ltd ADS
01/06/201514:21Business WireLa Commission européenne approuve la désignation orpheline pour le PBT2 dans le cadre de la maladie de HuntingtonNASDAQ:PRANPrana Biotechnology Ltd ADS
01/06/201512:20Business WireEuropäische Kommission gewährt PBT2 Orphan-Status für Chorea HuntingtonNASDAQ:PRANPrana Biotechnology Ltd ADS
01/06/201510:00Business WireEuropean Commission Approves PBT2 Orphan Designation for Huntington’s DiseaseNASDAQ:PRANPrana Biotechnology Ltd ADS
28/04/201500:22Business WirePBT2 Recommended for Orphan Designation in EuropeNASDAQ:PRANPrana Biotechnology Ltd ADS
19/11/201414:00Business WireThe Lancet Neurology Publishes Prana's Huntington Disease TrialNASDAQ:PRANPrana Biotechnology Ltd ADS
05/09/201410:49Dow Jones NewsU.S. Hot Stocks: Hot Stocks to WatchNASDAQ:PRANPrana Biotechnology Ltd ADS
05/09/201408:45PR Newswire (US)Prana receives FDA Orphan Drug Designation for PBT2 for Huntington DiseaseNASDAQ:PRANPrana Biotechnology Ltd ADS
17/07/201417:10PR Newswire (US)Prana Alzheimer's disease Development Program updateNASDAQ:PRANPrana Biotechnology Ltd ADS
14/05/201408:30PR Newswire (US)World leader in movement disorders Professor Ira Shoulson joins Prana BoardNASDAQ:PRANPrana Biotechnology Ltd ADS
23/04/201410:01Business WireZeldes Haeggquist & Eck LLP Announces Investigation of Prana Biotechnology LimitedNASDAQ:PRANPrana Biotechnology Ltd ADS
31/03/201418:03Dow Jones NewsMARKET SNAPSHOT: U.S. Stocks Rise; S&P 500, Nasdaq Notch Quarterly GainsNASDAQ:PRANPrana Biotechnology Ltd ADS
 Apresentando as notícias mais relevantes sobre:NASDAQ:PRAN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
BRKM5
BRASKEM PNA
BOV
HOOT4
HOTEIS OTHON PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios